HOME >> MEDICINE >> NEWS
Ecstasy can trigger heart attacks in users

The illegal drug MDMA (Methylene 3, 4 dioxy-methamphetamine) more commonly known as "Ecstasy" or "XTC," can trigger heart attacks, according to a case report in the December issue of Annals of Emergency Medicine. The case report describes a 27-year-old male who sought treatment at an emergency department after experiencing symptoms of chest tightness and discomfort for three hours.

The man reported that prior to experiencing these symptoms he drank a bottle of whisky and taken half of a pill of MDMA. He was diagnosed and treated in the emergency department for acute myocardial infarction as a result of MDMA use. This is only the second case reported showing evidence that MDMA can cause heart attacks similar to those caused by amphetamines, according to the report's authors. (Methylene 3, 4 Dioxy-Methamphetamine-Induced Acute Myocardial Infarction, p. 759)

The role of MDMA on coronary vessels is not well documented. However, the case report's authors from the National Taiwan University Hospital in Taipei, Taiwan, speculate that MDMA-related heart attacks may be similar to those caused by cocaine or amphetamine use. Other studies have found cocaine and amphetamines promote coagulation of blood that can lead to blood clots in the arteries, which can cause heart attacks.

Physicians in the emergency department should become familiar with this drug because of its emerging trend toward its use, advise the case report's authors. Although it was once thought that the drug does not cause dependency and adverse side effects, this belief has been overturned by many reports of side effects in recent literature, the report further explains.


'"/>

Contact: Colleen Hughes
chughes@acep.org
202-728-0610
American College of Emergency Physicians
26-Nov-2003


Page: 1

Related medicine news :

1. Ecstasy users get advice from friends and web not parents
2. Ecstasy affects memory, new international study shows
3. Rat study shows exposure to Ecstasy early in pregnancy induces brain, behavior changes
4. Taking Ecstasy during pregnancy may cause brain damage, behavior problems in babies
5. Ecstasy may be drug of choice for those trying to cope with lonelienss, study finds
6. Its winning, not losing, that triggers violence at sports events
7. Suppressing the cells that trigger cat allergy
8. Study: Eye contact triggers threat signals in autistic childrens brains
9. Mood elevating hormone may trigger depression and heart problems
10. Jefferson scientists uncover potential trigger of diabetic kidney disease
11. High levels of airborne mouse allergen in inner-city homes could trigger asthma attacks

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Ecstasy can trigger heart attacks users

(Date:6/19/2013)... Chrysler made news recently when it refused ... million Jeeps. The Jeep models in question are the 1993-2004 ... to the NHTSA are vulnerable to fire and explosion in ... are rear-mounted and have been alleged to catch fire or ... Cherokee with 32 rear-end crashes, which resulted in 44 deaths ...
(Date:6/19/2013)... CA (PRWEB) June 19, 2013 According to ... for Surviving Weekend Sunburn,” it is not uncommon for a ... the summer months. A person is likely to forget to ... , which is both dry and itchy. When this occurs, ... (Go to goo.gl/gDyjP). , “Most people do not realize that ...
(Date:6/19/2013)... a study published in the June 19 online edition ... led by researchers from the University of California, San ... events that take place when cardiac regeneration occurs in ... evidence that various cell lines in the heart are ... types, than previously thought. , More importantly, the research ...
(Date:6/19/2013)... This news release is available in Spanish . ... the field of neglected diseases, it goes by the name ... health research was devoted to conditions that accounted for 90 ... counteract this imbalance that the Drugs for Neglected Diseases initiative ... anniversary year, the organization has been granted the BBVA Foundation ...
(Date:6/19/2013)... California (PRWEB) June 19, 2013 Effective Environmental ... launch of new websites. These online links are devoted to ... Septic Tank cleaner, Organic Odor Control Mold Magician and others. ... for fish and animals in the water as well as ... and sludge buildup that can accumulate at the bottom of ...
Breaking Medicine News(10 mins):Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 2Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 3Health News:Skin Care – How to treat Sunburn 2Health News:Fate of the heart: Researchers track cellular events leading to cardiac regeneration 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 3Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 4Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 5Health News:Effective Environmental Services Launch New Websites to Serve Customers 2
(Date:6/19/2013)... --  Nektar Therapeutics (Nasdaq: NKTR ) today ... study for NKTR-181, a first-in-class, opioid analgesic molecule ... slow rate of entry is designed to reduce the euphoria ... current opioid analgesics. 1 In the study data being ... in "drug liking" and "feeling high" scores and had highly ...
(Date:6/19/2013)... 2013 BD Biosciences, a segment of BD (Becton, ... global medical technology company, today announced the launch of the ... its line of high-performance research flow cytometers. ... with the most compact footprint in its class at just ... of 30" (76.2 cm). Recognizing that space is a valuable ...
(Date:6/19/2013)... ZIONA, Israel , June ... announced that results from a phase I study in ... in advanced Parkinson,s patients, of ND0612, were presented at ... Disorders. ND0612 is a proprietary levodopa/carbidopa liquid drug formula ... delivery patch that would maintain constant levodopa plasma concentrations. ...
Breaking Medicine Technology:Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6
Cached News: